Delve Health invests in and develops digital endpoints and AI layers that improve endpoint sensitivity, reduce operational risk, and extend evidence generation across the drug lifecycle—from Phase II/III execution to post-market follow-up and real-world evidence.
We do not develop drugs. We develop the digital endpoints, AI intelligence, and operational systems that de-risk clinical development and strengthen evidence packages—especially in programs where remote measures, adherence, and real-world signals matter.
Digital endpoints only create value when operationalized end-to-end. Our R&D focuses on signal integrity, compliance, auditability, and correlation to clinically meaningful outcomes—then scales those workflows across programs.
A staged view of our R&D efforts—from endpoint thesis formation through AI intelligence and post-market evidence workflows—built to support drug programs across therapeutic areas.
Identify where digital measures can materially strengthen endpoints and trial execution.
Translate hypotheses into measurable, auditable endpoints for Phase II/III designs.
Turn raw trial data into decision-grade insight for development and clinical operations.
Extend evidence generation beyond approval and strengthen long-term monitoring and RWE.
Delve Health invests in and develops digital endpoints and AI infrastructure that de-risk clinical development, accelerate evidence generation, and improve post-approval adoption across multiple drug classes.
We advance initiatives only when we can operationalize the full chain of evidence—signal integrity, compliance, auditability, and correlation to clinically meaningful outcomes.
Our R&D priorities align to areas where digital endpoints can increase endpoint sensitivity, reduce missing data, and strengthen evidence packages for development teams and medical affairs.
Arrhythmia burden, functional tolerance, physiologic trends, patient adherence.
Fatigue and functional decline, cardiotoxicity signals, symptom-linked monitoring.
Sleep, activity patterns, behavior-linked adherence, sustained engagement at scale.
Home monitoring, symptom-linked measures, engagement support for chronic programs.
If you are reviewing companies for JPM Bio access, we can share a concise overview of our R&D pipeline, current programs, and how our digital endpoints and AI layers support drug development and lifecycle evidence.